{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/54216071"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "An in vitro hollow-fiber infection model that replicates the pharmacokinetic profile of levofloxacin observed in humans (half-life [t1/2], 7.5 h) or in animals, such as the mouse or the rhesus monkey (t1/2, ???2 h), was used to evaluate a proposed indication for levofloxacin (500 mg once daily) for the treatment of Bacillus anthracis infections." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "pubmedcentralcanada.ca" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/161063516"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/54216071"] } } }
